IMR Press / FBL / Volume 15 / Issue 1 / DOI: 10.2741/3607

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma

Show Less
1 Division of Digestive Endoscopy/Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, 277-8577, Japan
2 Department of Gastroenterology, Showa University School of Medicine, Tokyo, 142-8666, Japan
3 Clinical Research Laboratory, Showa University School of Medicine, Tokyo, 142-8666, Japan
4 Division of Pathology, Showa University School of Medicine, Tokyo, 142-8666, Japan
5 Promotion Center of Pharmaceutical Education, School of Pharmaceutical Sciences, Showa University, Tokyo, 142-8666, Japan
6 Institute of Molecular Oncology, Showa University School of Medicine, Tokyo, 142-8666, Japan
7 Department of Environmental Health, University of Occupational and Environmental Health, Kitakyushu, 807-8555, Japan
8 Global COE, Nagoya University School of Medicine, Nagoya, 466-8550, Japan
Academic Editor:Norio Kagawa
Front. Biosci. (Landmark Ed) 2010, 15(1), 65–72;
Published: 1 January 2010
(This article belongs to the Special Issue Gene regulation and structure-function of P450 Cold stress response)

Esophageal squamous cell carcinoma (ESCC) exhibits abnormalities in epidermal growth factor receptor (EGFR) gene. To identify a prognostic marker, the overexpression of EGFR protein, mutations in EGFR and p53 mutations were analyzed in pretreatment biopsy specimens removed from T3-4 and/or M1 LYM ESCC patients who received chemoradiotherapy. A silent mutation comprised of a single nucleotide polymorphism (SNP) at codon 787 of exon 20 of the EGFR gene was found in 19 patients (33%). In multivariate analysis, a significant difference was seen in the overall survival (odds ratio; 2.347, 95% confidence interval; 1.183-4.656, p = 0.015) between patients with and without the EGFR heterozygous genotype. Among the 57 eligible patients, 3-year survival rates was 21%, while in patients with EGFR heterozygous genotype the rate were 0%. However, neither overexpression of EGFR nor p53 mutations was associated with the overall survival. These results suggest that the EGFR SNP at codon 787 of exon 20 determined in pretreatment biopsy specimens may be a clinically useful biomarker for predicting the prognosis of ESCC patients.

Back to top